A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis

Olsen, Elise A.; Cram, David L.; Ellis, Charles N.; Hickman, Janet G.; Jacobson, Coleman; Jenkins, Evelyn E.; Lasser, Alan E.; Lebwohl, Mark; Leibsohn, E; Medansky, Roland S.; Oestreicher, Mark I.; Savin, Ronald C.; Scher, Richard K.; Shavin, Joel S.; Smith, Ronald D.; Day, Robert M.

doi:10.1016/0190-9622(91)70069-e

Cited by 59 publications

(46 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixteen controlled trials of topical corticosteroids in the treatment of scalp psoriasis have been published. The most frequently used corticosteroids that have been studied in blind placebo-controlled trials of 2-4 weeks duration are betamethasone dipropionate or valerate, fluocinolone acetonide, mometasone furoate and clobetasol propionate [15,16,17,18,19,20]. No studies are available to support the safety of the topical corticosteroid effect on the scalp after 4 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…No studies are available to support the safety of the topical corticosteroid effect on the scalp after 4 weeks. Clobetasol propionate 0.05% and betamethasone dipropionate 0.05% are among the most potent topical corticosteroid preparations currently used [17,21]. Long-term use of mid-potency preparations or intermittent use of potent steroids is more commonly practiced by physicians [8].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ustekinumab Induces Fast Response and Maintenance of Very Severe Refractory Scalp Psoriasis: Results in Two Greek Patients from the Psoriasis Hospital-Based Clinic

Papadavid¹,

Ferra²,

Koumaki³

et al. 2014

Dermatology

View full text Add to dashboard Cite

Background: Scalp psoriasis, one of the most common sites of psoriasis involvement, is often difficult to control with topical agents. There is a lack of substantial evidence-based data for the efficacy and safety of systemic therapies. Methods: Two patients from our university-based psoriasis clinic with chronic plaque psoriasis and severe recalcitrant scalp involvement were assessed by Psoriasis Area and Severity Index and Psoriasis Scalp Severity Index scores, respectively, and quality of life by the Dermatology Life Quality Index. Results: We report 2 psoriasis patients with very severe scalp psoriasis who developed a fast clinical response of scalp psoriasis to ustekinumab in 8 weeks with excellent patient adherence up to 28 weeks of follow-up and positive impact on quality of life due to rapid and long-term clearing. Conclusion: Ustekinumab produces a fast clinical response of recalcitrant scalp psoriasis with excellent patient adherence and a positive impact on quality of life due to rapid and long-term clearing in patients with very severe scalp involvement who failed conventional topical and systemic treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Ustekinumab Induces Fast Response and Maintenance of Very Severe Refractory Scalp Psoriasis: Results in Two Greek Patients from the Psoriasis Hospital-Based Clinic

Papadavid¹,

Ferra²,

Koumaki³

et al. 2014

Dermatology

View full text Add to dashboard Cite

show abstract

“…We expect that patients using Skin Cap were more compliant given that it was thought that it was 'steroid-free' and had no potential for adverse events. Indeed, in clinical trial situations, where highly motivated subjects can be expected to have greater compliance than is observed in clinical practice, clobetasol propionate solution exhibits a high efficacy rate with 80% of subjects having at least 50% improvement in 2 weeks [8,14].…”

Section: Discussionmentioning

confidence: 99%

Bioavailability of Clobetasol Propionate in Different Vehicles

Franz¹,

Lehman²,

Feldman

et al. 2003

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Topical clobetasol propionate is widely used for the treatment of psoriasis. One formulation of clobetasol propionate, Skin Cap, was thought by some practitioners and patients to be more effective than other formulations. Differences in corticosteroid bioavailability could account for differences in efficacy. The purpose of this study is to compare the relative bioavailability of clobetasol propionate from Skin Cap to two FDA-approved formulations of clobetasol propionate (Olux foam and Temovate scalp application). The bioavailability was assessed by measuring the percutaneous absorption of clobetasol propionate in vitro on scalp skin, using the human cadaver skin model. There was no significant difference in the percutaneous absorption of clobetasol propionate between Olux foam and Skin Cap (2.09 and 1.93% at 48 h, respectively) or between Olux foam and Temovate scalp application (3.70 and 3.46%, respectively) when applied under unoccluded conditions. Under occluded conditions, there was greater absorption of clobetasol propionate from the Olux foam as compared with Skin Cap (4.94 and 1.57%, respectively; p < 0.05). The Skin Cap vehicle does not provide more bioavailable clobetasol propionate than currently available, FDA-approved products. Other differences, including those in patient compliance, could account for the perceived efficacy of the product.

show abstract

“…The total score was determined by addition of the different numerical values [4,14]. The physician's evaluations were done before the start of therapy (baseline) and on days 4, 7, 10, 14, 18, and 21.…”

Section: Methodsmentioning

confidence: 99%

“…Adverse events, if any, were recorded at each visit. The patient's assessment of satisfaction at the end of treatment was recorded on a 3-point score (very content, moderately content, discontent; table 4) [14].…”

Section: Methodsmentioning

confidence: 99%

Dithranol in an Emulsifying Oil Base (Bio-Wash-Oil) for the Treatment of Psoriasis of the Scalp

Wulff-Woesten

Ohlendorf²,

Henz³

et al. 2004

Skin Pharmacol Physiol

View full text Add to dashboard Cite

On the scalp, dithranol has been studied in only a few trials. The dithranol molecule that contains both hydrophilic and lipophilic centers can be incorporated into detergents and allows easy removal from hair. This property has led to the incorporation of dithranol in an emulsifying oil base (bio-wash-oil). The formulation has been used routinely for more than two decades in East Germany. We reexamined the efficacy and safety of dithranol in bio-wash-oil and compared it to dithranol embedded in crystalline monoglycerides (Micanol^®) in patients with psoriasis of the scalp. In a prospective, parallel group study, 64 patients attending a day-care clinic were randomly allocated to 3 treatment groups: (1) dithranol in bio-wash-oil; (2) Micanol^® cream, and (3) Micanol^® cream in bio-wash-oil. Treatment was carried out for 3 weeks and results assessed using a modified Psoriasis Area and Severity Index score. Dithranol in bio-wash-oil resulted in a reduction in the score of 34% on day 7 and 57% on day 14. This was significantly better than in groups 2 and 3, as were the overall response and patients’ assessment at the end of treatment (p < 0.05). Dithranol in a bio-wash-oil is an effective, well-tolerated and low-priced treatment in psoriasis of the scalp.

show abstract

A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis

Cited by 59 publications

References 8 publications

Ustekinumab Induces Fast Response and Maintenance of Very Severe Refractory Scalp Psoriasis: Results in Two Greek Patients from the Psoriasis Hospital-Based Clinic

Ustekinumab Induces Fast Response and Maintenance of Very Severe Refractory Scalp Psoriasis: Results in Two Greek Patients from the Psoriasis Hospital-Based Clinic

Bioavailability of Clobetasol Propionate in Different Vehicles

Dithranol in an Emulsifying Oil Base (Bio-Wash-Oil) for the Treatment of Psoriasis of the Scalp

Contact Info

Product

Resources

About